HISAMITSU PHARMACEUTICAL CO.,INC.

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from was processed by Pulse News Wire on February 13, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

HISAMITSU PHARMACEUTICAL CO.,INC. Announces Share Consolidation, Sets Delisting Date

Source disclosure: February 13, 2026 HISAMITSU PHARMACEUTICAL CO.,INC. [4530.T] TOKYO — HISAMITSU PHARMACEUTICAL CO., INC. announced on February 13, 2026, that it has set the record date for its extraordinary general meeting scheduled to be held around mid-April 2026. The company's board of directors made this decision during a meeting held today. The record date will be set as February 28, 2026 (Saturday), although due to the holiday, the practical day will be February 27, 2026 (Fr